人参
五加科
活性成分
传统医学
成分
药理学
转移
肺癌
医学
癌症
内科学
肿瘤科
病理
替代医学
作者
Shahar Lev‐Ari,Alexander Starr,Akiva Vexler,Lital Kalich‐Philosoph,Hwa‐Seung Yoo,Ki-Rok Kwon,Meital Yadgar,Ekaterina Bondar,Amir Bar‐Shai,Ilan Volovitz,Yehuda Schwarz
出处
期刊:Food & Function
[Royal Society of Chemistry]
日期:2021-01-01
卷期号:12 (17): 8068-8077
被引量:16
摘要
BACKGROUND AND OBJECTIVE: While there are multiple studies on the anti-tumoral effects of Panax ginseng as active ingredients (one or more ginsenosides derived from the extract) or as a whole plant extract, there is a lack of studies to assess the effects Panax ginseng's of active ingredients combined with the whole plant extract. Our aim was to study the effect of whole ginseng, enriched in the anti-tumoral Rh2 component and other ginsenosides (Ginseng Rh2+), on the metastatic capacity of non-small cell lung cancer (NSCLC). METHODS: ) on days 6, 10, and 14 after tumor injection. RESULTS: We found that Ginseng Rh2+ increased the apoptosis of NSCLC cells in vitro, demonstrating dose dependent down-regulation of the Bcl-2 anti-apoptotic gene and concurrent up-regulation of the Bax pro-apoptotic gene. Ginseng Rh2+ inhibited the tumor cells' capacity to attach to the ECM-related matrix and reduced cell migration. In vivo, Ginseng Rh2+ inhibited local tumor growth and reduced the development of experimental lung metastases. CONCLUSION: Our study suggests that Ginseng Rh2+ may potentially be used as a therapeutic agent for treatment of NSCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI